Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma
In Vitro
and
In Vivo
.
Cancers
2022,
14
, 2959
Cancers (Basel)
.
2023 Feb 13;15(4):1182.
doi: 10.3390/cancers15041182.
Authors
Shiri Davidi
1
,
Sara Jacobovitch
1
,
Anna Shteingauz
1
,
Antonia Martinez-Conde
1
,
Ori Braten
1
,
Catherine Tempel-Brami
1
,
Einav Zeevi
1
,
Roni Frechtel-Gerzi
1
,
Hila Ene
1
,
Eyal Dor-On
1
,
Tali Voloshin
1
,
Itai Tzchori
1
,
Adi Haber
1
,
Moshe Giladi
1
,
Adrian Kinzel
2
,
Uri Weinberg
1
,
Yoram Palti
1
Affiliations
1
Novocure Ltd., Haifa 3190500, Israel.
2
Novocure GmbH, 81925 Munich, Germany.
PMID:
36831698
PMCID:
PMC9954138
DOI:
10.3390/cancers15041182
Abstract
The authors wish to make minor corrections to Figure 1 and Figure 2 of the following paper [...].
Publication types
Published Erratum
Grants and funding
Not applicable/Novocure (United States)